Intermittent treatment regime for organ failure
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 8, 2005
app pub date -
Aug 26, 2004
filing date -
Jun 8, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method of treating patients with coronary heart failure (CHF) by the intermittent administration of Angiotensin Converting Enzyme (ACE) inhibitors and/or angiostatin II receptor agonists (ARBs) is disclosed. The ACE inhibitor is administered to the patient during a treatment period and the levels of hematopoietic stem cells (HSC) in the patient's blood is determined. Treatment with the ACE inhibitor is discontinued (during a recovery period) when the measured level of hematopoietic cells drops below a given point and is re-administered when levels rise above a given point. Alternating, treatment and recovery periods can be repeated a plurality of times. Levels of HSC may be determined based on ACE.sup.+ cell levels or by monitoring CD34 levels and the results used to determine optimum points for the administration of drugs which reduce HSC levels.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully